TR200100338T2 - Ödem tedavisinde kullanılan TNF-türevleri peptitler. - Google Patents

Ödem tedavisinde kullanılan TNF-türevleri peptitler.

Info

Publication number
TR200100338T2
TR200100338T2 TR2001/00338T TR200100338T TR200100338T2 TR 200100338 T2 TR200100338 T2 TR 200100338T2 TR 2001/00338 T TR2001/00338 T TR 2001/00338T TR 200100338 T TR200100338 T TR 200100338T TR 200100338 T2 TR200100338 T2 TR 200100338T2
Authority
TR
Turkey
Prior art keywords
tnf
edema
alpha
treatment
present
Prior art date
Application number
TR2001/00338T
Other languages
English (en)
Turkish (tr)
Inventor
Lucas Rudolf
Baetseller Patrick
Pugin Jerome
Bloc Alain
Fransen Lucie
Original Assignee
Innogenetics N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics N.V. filed Critical Innogenetics N.V.
Publication of TR200100338T2 publication Critical patent/TR200100338T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TR2001/00338T 1998-08-14 1999-08-10 Ödem tedavisinde kullanılan TNF-türevleri peptitler. TR200100338T2 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98870180 1998-08-14
EP98870198 1998-09-18
EP98870222 1998-10-21

Publications (1)

Publication Number Publication Date
TR200100338T2 true TR200100338T2 (tr) 2001-12-21

Family

ID=27239778

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00338T TR200100338T2 (tr) 1998-08-14 1999-08-10 Ödem tedavisinde kullanılan TNF-türevleri peptitler.

Country Status (20)

Country Link
US (2) US20030105021A1 (enExample)
EP (3) EP1105152A1 (enExample)
JP (1) JP4542266B2 (enExample)
CN (1) CN1181886C (enExample)
AT (2) ATE395072T1 (enExample)
AU (1) AU764992B2 (enExample)
BR (1) BR9912899A (enExample)
CA (1) CA2334941C (enExample)
CZ (1) CZ302862B6 (enExample)
DE (2) DE69938743D1 (enExample)
DK (1) DK1264599T3 (enExample)
ES (1) ES2296872T3 (enExample)
HU (1) HU227661B1 (enExample)
IL (2) IL141064A0 (enExample)
NZ (1) NZ509604A (enExample)
PL (1) PL203706B1 (enExample)
PT (1) PT1264599E (enExample)
TR (1) TR200100338T2 (enExample)
WO (1) WO2000009149A1 (enExample)
ZA (1) ZA200100656B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227661B1 (hu) 1998-08-14 2011-10-28 Rudolf Lucas Dr TNF-eredetû peptidek ödéma kezelésére
CA2575513C (en) * 2004-08-06 2014-09-16 Altana Pharma Ag Composition comprising a pulmonary surfactant and a tnf-derived peptide
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT506151B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Fusionsprotein
AT506150B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
AT507953B1 (de) * 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
AT509267A1 (de) 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh Organische verbindungen zur regulierung von vektoriellen ionenkanälen
DK2397151T3 (en) 2010-06-21 2015-05-18 Apeptico Forschung & Entwicklung Gmbh The treatment of the vascular complications of diabetes
AT510585B1 (de) * 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
US11161881B2 (en) * 2010-11-18 2021-11-02 Apeptico Forschung Und Entwicklung Gmbh Composition comprising a peptide and an inhibitor of viral neuraminidase
EP2679239A1 (de) * 2012-06-28 2014-01-01 Apeptico Forschung und Entwicklung GmbH Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
US12004506B2 (en) 2013-04-23 2024-06-11 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
CN105188735A (zh) * 2013-04-23 2015-12-23 阿佩普蒂科研究和开发有限责任公司 包含式x1-gqretpegaeakpwy-x2的环肽的药物组合物及其体外处理肺的用途
CA2940351A1 (en) 2014-03-18 2015-09-24 Apeptico Forschung Und Entwicklung Gmbh Dry-powder peptide medicament
CN110613838A (zh) * 2018-06-19 2019-12-27 姜石松 增强细胞通透性的多肽及其应用
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
IL294894A (en) 2020-05-08 2022-09-01 Apeptico Forschung & Entwicklung Gmbh A peptide for the prevention or treatment of covid-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE384179C (de) * 1921-04-07 1923-10-27 Ludwig Weil Dr Laufrad fuer Kreiselpumpen und -geblaese
DE3841759A1 (de) 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
US5891679A (en) 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
HU227661B1 (hu) 1998-08-14 2011-10-28 Rudolf Lucas Dr TNF-eredetû peptidek ödéma kezelésére

Also Published As

Publication number Publication date
CZ2001538A3 (cs) 2001-08-15
HK1051805A1 (en) 2003-08-22
CN1181886C (zh) 2004-12-29
EP1105152A1 (en) 2001-06-13
EP1264599A1 (en) 2002-12-11
US20030185791A1 (en) 2003-10-02
HUP0103117A3 (en) 2004-03-01
DK1264599T3 (da) 2008-02-04
WO2000009149A1 (en) 2000-02-24
DE69937206D1 (de) 2007-11-08
IL141064A (en) 2009-09-01
EP1247531B1 (en) 2008-05-14
PL345997A1 (en) 2002-01-14
ATE374039T1 (de) 2007-10-15
US7258861B2 (en) 2007-08-21
ZA200100656B (en) 2005-06-29
HU227661B1 (hu) 2011-10-28
ATE395072T1 (de) 2008-05-15
JP4542266B2 (ja) 2010-09-08
ES2296872T3 (es) 2008-05-01
EP1264599B1 (en) 2007-09-26
BR9912899A (pt) 2001-05-08
CA2334941C (en) 2011-08-09
PL203706B1 (pl) 2009-11-30
NZ509604A (en) 2003-05-30
JP2002522508A (ja) 2002-07-23
AU5620999A (en) 2000-03-06
EP1247531A3 (en) 2002-12-18
IL141064A0 (en) 2002-02-10
CZ302862B6 (cs) 2011-12-21
DE69937206T2 (de) 2008-06-19
EP1247531A2 (en) 2002-10-09
DE69938743D1 (de) 2008-06-26
CA2334941A1 (en) 2000-02-24
HUP0103117A2 (hu) 2001-12-28
US20030105021A1 (en) 2003-06-05
AU764992B2 (en) 2003-09-04
PT1264599E (pt) 2008-01-07
CN1312724A (zh) 2001-09-12

Similar Documents

Publication Publication Date Title
DK1337157T3 (da) Proteinhydrolysater
DK1264599T3 (da) TNF-afledte peptider til anvendelse i behandling af ödem
ES2160485A1 (es) Peptidos inhibidores de la exorcitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
CY1107668T1 (el) Χρηση αμινοξικων αντισπασμωδικων για τη θεραπευτικη αγωγη του πονου
NZ333609A (en) Peptide inhibitors of the interaction between P35 and MDM2 and the treatment of tumor cells
HUP0000492A1 (hu) N-(Aril/heteroaril-acetil)-aminosav-észterek, azokat tartalmazó gyógyászati készítmények, valamint módszerek béta-amiloid fehérje képződése és felszabadulása gátlására e vegyületek felhasználásával
DE60331546D1 (de) Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung
ATE350396T1 (de) Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung
DE60213648D1 (de) Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln
BR0012418A (pt) Derivados de peptìdeo cìclicos como inibidores de integrina alfavbeta6
BR122013026957A2 (enExample)
ATE443076T1 (de) Von protease typ ii spaltbares peptid
DE60231825D1 (de) Behandlung von infektionen verursacht von mikroorganismen
TW326395B (en) Water-based hair treatment composition as heat-safe preparation and method of using same
ATE198987T1 (de) Behandlung von tropikalischer spastischer paresis mit peptide t
DE69330268D1 (de) Hämoregulierende peptide
DE60104695D1 (de) Zusammensetzungen aus aminosäuren zur behandlung von herzinsuffizienz
ATE218334T1 (de) Verwendung von gabapentin in der behandlung vonangst - und panikstörungen
AU2003264535A1 (en) Tumor antigen protein and utilization thereof
SE9901773D0 (sv) Förebyggande av karies i tänderna
SE0002232D0 (sv) Antioxidant
DE60008749D1 (de) Therapeutische peptide aus untersequenzen von bpi